Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Yong Xiao Wang

Yong Xiao Wang

Albany Medical College USA

Kun Qing

Kun Qing

University of Virginia USA

Hwa Mu Lee

Hwa Mu Lee

Western University Health Science USA

Vasileios Andrianopoulos

Vasileios Andrianopoulos

Schoen Klinik Berchtesgadener Land Germany

Shigeo Takizawa

Shigeo Takizawa

Biophilia Institute Japan

Rakesh Gupta

Rakesh Gupta

Department of Health & Family Welfare India

Uma Hariharan

Uma Hariharan

Ram Manohar Lohia Hospital India

Ginika Egesimba

Ginika Egesimba

Institute of Tropical Medicine Nigeria

Copd 2019

About Conference

Conference Series Ltd  is overwhelmed to announce the commencement of 9th International Conference on COPD and Lungs” to be held during March 11-12, 2019 in Singapore. The upcoming conference will be organized around the theme "Every breath counts: Halt the rise of COPD".

Conference Series Ltd organizes 1000+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

COPD 2019 conference brings together individuals who have an interest in the field of Respiratory and Pulmonary Disease relating to diversified topics like COPD, emphysema, asthma, cystic fibrosis, lung cancer, other pulmonary diseases and therapeutics. It is a forum to explore issues of mutual concern as well as exchange knowledge, share evidence and ideas, and generate solutions.

Target Audience:

This event is suited to anyone with an academic or professional interest in COPD and its research; including Researchers, Senior scientists, Pulmonologists, Professors, Doctors, Nurses, Healthcare Professionals, Pharmacologists, Clinicians, Directors of Association and Societies, Postgraduate students and those who work in research and development of pharmaceuticals and related technology

Why to Attend???

COPD 2019 conference is an opportunity to meet others within speciality to network and to learn the latest clinical information.

With members from around the world focused on learning about pulmonary care and its advances; this is your best opportunity to reach the largest assemblage of participants from the Respiratory community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new discoveries in the COPD treatment and diagnosis, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in the world of Respiratory care are hallmarks of this conference.

Scope and Importance:

Pulmonary health has a particular interest on the impact changes in respiratory care and the awareness is increasing every year, and therefore COPD 2019 encourages submissions from researchers based in USA, Europe and Asian countries.

The challenge of the field is to evaluate current promising interventions rigorously, address emerging issues such as synthesizing ever-increasing research findings, and develop innovative dissemination and communication strategies.

The journal invites submissions on research in COPD, including emphysema, tuberculosis, asthma, pulmonary rehabilitation, cystic fibrosis, lung cancer and topics related to respiratory health.

COPD 2019 provides a platform that helps authors to share their knowledge with a wider audience, and sustains a rapid process for submissions resulting in high quality publications. We further aim to contribute towards reducing the inequity in publications from low- and middle-income countries. Our audience is global and we intend to share research results in COPD from all parts of the world.

Market Analysis

Major COPD Research Associations around Asia Pacific

COPD Patient Organization of Vietnam

COPD Patients Club Kyrgyzstan

COPD Club of Northern Thailand

Asian Pacific Society of Respirology

Chinese COPD Patient Education Organziation

Major COPD Research Associations around Globe

Alpha-1 Foundation

American Association for Respiratory Care

American College of Chest Physicians

American College of Emergency Physicians

American College of Physicians

American Lung Association

Canadian Lung Association (CLA)

COPD Foundation

Target Audience:

• Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments

• COPD Students, Scientists, Faculty

• Medical Colleges

• COPD Associations and Societies

• Business Entrepreneurs, Pharmaceutical companies

Universities Associated with COPD 2017

Major Universities on COPD Research

Kumamoto University, Japan

Tokyo National Hospital, Japan

KindaiUniversity, Japan

Okayama University, Japan

Medi7 Bentleigh, Australia

Macquarie University, Australia

Australian national university, Australia

Charles Darwin University Casoria Australia

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Iqbal Chest Centre, Bangladesh

Imperial College London, United Kingdom

Linnaeus University, Sweden

University Of California Los Angeles, United States

Columbia University Medical Center, United States

Harvard University, United States

Global Market research on COPD

The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach

a value of $15.6 billion by 2019. The drugs driving this growth include once-daily LABA/LAMA

fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein.

North America leads the global market for asthma &COPD drugs and devices. North America was followed by Europe in terms of market capitalization. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.

The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. The COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.

In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment.

Top few companies in this global market:



F. Hoffmann-La Roche

Novartis and Merck




Boehringer Ingelheim







Global COPD & Asthma Devices Market, By Product



Inhalers accounted for the major market and is expected to continue its dominance till 2020

Global COPD & Asthma Devices Market, By Geography

North America




LAMEA region would exhibit the highest CAGR of 4.9% during 2017-2020

Past Conference Report

Copd 2018

Conference series LLC Ltd successfully hosted for "6th International conference on Chronic obstructive pulmonary disease" during May 17-18, 2018, Tokyo, Japan. COPD 2018 conference was organized around the theme "COPD Today: Clinical and Research Issues" and it was a great success where eminent keynote speakers from various reputed organizations made their resplendent presence and addressed the gathering.

COPD 2018 was marked by the attendance of Editorial Board Members of supported Journals like Journal of Pulmonary & Respiratory Medicine, Journal of Lung Diseases & Treatment and Journal of Pulmonary Medicine. Many Scientists, young and brilliant Researchers, Business Delegates and talented Student Communities representing from varies countries made this conference fruitful and productive driving the three-day event into the path of success with thought provoking keynote and plenary presentations.

6th International conference on Chronic Obstructive Pulmonary Disease covered the following scientific sessions and discussions:

Lung Diseases

Asthma and allergy

Cardiovascular Risk and COPD

Pathogenesis of COPD

Lung cancer

Airway and Therapeutic Devices

CO-Morbidities in COPD

Management of COPD

Pulmonary diseases-Treatment and therapies

COPD Exacerbations

Diagnostic Evaluation of COPD

Paediatric Pulmonary, Critical care and Sleep

Epidemiology of COPD

Pulmonary Hypertension

Environmental and Occupational lung Disease

COPD Therapeutics

Lung Transplantation

Self-Management and Prevention of COPD

COPD 2018 Organizing Committee would like to thank the Moderator of the conference.

Yong –Xiao Wang

Albany Medical College, USA

Hwa Mu Lee

Western University Health Science, USA

Rakesh Gupta

Department of Health & Family Welfare, India

With the feedback from the participants and supporters of COPD 2018, Conference series LLC Ltd is glad to announce 9th International Conference on COPD and Lungs (COPD 2019) during March 11-12, 2019 in Singapore. COPD 2019 will cover some of the most challenging topics and advancements in research in the fields of Pulmonary and Respiratory medicine.


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date March 11-12, 2019

Speaker Opportunity

Supported By

Journal of Pulmonary & Respiratory Medicine Journal of Lung Diseases & Treatment Journal of Pulmonary Medicine

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by